All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.

Judith TrotmanExecutive Steering Committee Member

Professor Judith Trotman is a Senior Staff Specialist and Director of the Clinical Research Unit in the Haematology Department, Concord Repatriation General Hospital, Sydney, AU. She has particular expertise in the management of lymphoid malignancies.

Prof. Trotman and colleagues have built one of the largest clinical research units in Australia for collaboration in a broad portfolio of hematological trials. She is a member of the Australasian Leukaemia and Lymphoma Group (ALLG) Scientific Advisory Committee and Chair of the Low-Grade Lymphoma Committee.  She is the ALLG Principal Investigator for several national trials and international lymphoma collaborations with French (PRIMA, REMARC), Italian (FOLLCOLL), and UK lymphoma cooperative groups, including the RATHL trial - Response Adapted Therapy in Hodgkin lymphoma — a study delivering PET-adapted therapy to patients with advanced Hodgkin lymphoma. She is a co-author of the International Imaging Guidelines in staging and response assessment of lymphoma and leads an international collaboration demonstrating the predictive power of both baseline and end-of-treatment PET in follicular lymphoma. She is currently trialing a PET-adapted approach in relapsed follicular lymphoma. Beyond lymphoma, she leads a study designed to optimize dosing of melphalan in myeloma transplantation. In this modern digital era, she is committed to facilitating cross-center collaboration in trial recruitment across the broad spectrum of rare hematological malignancies. She is the co-inventor of ClinTrial Refer — a non-profit, free-to-download application that has increased patient cross-referrals across numerous international cancer trial portfolios.